These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 16019715

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High-density lipoprotein: antioxidant and anti-inflammatory properties.
    Navab M, Yu R, Gharavi N, Huang W, Ezra N, Lotfizadeh A, Anantharamaiah GM, Alipour N, Van Lenten BJ, Reddy ST, Marelli D.
    Curr Atheroscler Rep; 2007 Sep; 9(3):244-8. PubMed ID: 18241620
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 5. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A, Chapman MJ.
    Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
    [Abstract] [Full Text] [Related]

  • 6. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease.
    Haas MJ, Mooradian AD.
    Diabetes Metab Res Rev; 2010 Feb; 26(2):90-9. PubMed ID: 20047197
    [Abstract] [Full Text] [Related]

  • 7. High-density lipoproteins, inflammation and oxidative stress.
    Tabet F, Rye KA.
    Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of high-density lipoprotein in inflammation.
    Navab M, Anantharamaiah GM, Fogelman AM.
    Trends Cardiovasc Med; 2005 May; 15(4):158-61. PubMed ID: 16099381
    [Abstract] [Full Text] [Related]

  • 10. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
    Barter PJ, Rye KA.
    J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein.
    Shah PK.
    Am J Cardiol; 2007 Dec 03; 100(11 A):S62-7. PubMed ID: 18047855
    [Abstract] [Full Text] [Related]

  • 14. HDL function as a target of lipid-modifying therapy.
    Watson KE, Ansell BJ, Watson AD, Fonarow GC.
    Rev Cardiovasc Med; 2007 Dec 03; 8(1):1-8. PubMed ID: 17401296
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG.
    Exp Clin Endocrinol Diabetes; 2005 Sep 03; 113(8):414-7. PubMed ID: 16151973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.